We are live on ! Find out more
APVO icon

Aptevo Therapeutics

5 hedge funds and large institutions have $22.8K invested in Aptevo Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.01%0% (-0.01%)

29% less funds holding

Funds holding: 75 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

89% less capital invested

Capital invested by funds: $209K → $22.8K (-$186K)

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$12.2K +$36.7K +29 New
TRCT
2
Tower Research Capital (TRC)
New York
$3.78K +$7.59K +6 +200%
CS
3
Clear Street
New York
$3.25K +$10.1K +8 New
Bank of America
4
Bank of America
North Carolina
$2.69K +$7.59K +6 New
SS
5
SBI Securities
Japan
$813 +$2.53K +2 New
BlackRock
6
BlackRock
New York
$28
Morgan Stanley
7
Morgan Stanley
New York
$4 -$13.9K -11 Closed
Osaic Holdings
8
Osaic Holdings
Arizona
$1
VF
9
Virtu Financial
New York
-$93K -60 Closed
HF
10
HRT Financial
New York
-$53K -34 Closed
JP Morgan Chase
11
JP Morgan Chase
New York
-$19.5K -13 Closed
DP
12
Diadema Partners
New Jersey
-$17.5K -11 Closed
UBS Group
13
UBS Group
Switzerland
-$3.38K -2 Closed
CFFP
14
Center for Financial Planning
Michigan
-$22
DB
15
Danske Bank
Denmark
-$4

APVO Hedge Fund Activity: Q1 2025 in Review

5 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2025, worth a combined $22.8K — down 89% from $209K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of APVO and 4 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $36.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $93K sold.

  • 5 institutional investors held Aptevo Therapeutics (APVO) as of Q1 2025, down from 7 in Q4 2024.
  • Funds reported $22.8K of Aptevo Therapeutics stock for Q1 2025, down 89% quarter-over-quarter.
  • 4 funds opened new Aptevo Therapeutics positions in Q1 2025 and 6 closed out, a net change of -2 holders.
  • The largest Aptevo Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $36.7K added.
  • The largest Aptevo Therapeutics seller in Q1 2025 was Virtu Financial, an estimated $93K sold.

Based on aggregated 13F filings for Q1 2025.